The anti-psychotic drug Risperdal (risperidone) has been associated with severe side effects, including gynecomastia (male breast growth), severe weight gain, and type-2 diabetes.
Johnson & Johnson Settles Risperdal Class Action Lawsuits
Johnson & Johnson (J&J) has lost four consecutive Risperdal class action lawsuits with Attorneys General in the following states: Texas ($158 million), South Carolina ($327 million), Arkansas ($1.2 billion, under appeal), and Louisiana ($257.7 million).
Prosecutors accused J&J of defrauding taxpayer-funded healthcare systems by using illegal marketing tactics to promote Risperdal over cheaper, equally-effective drugs. These tactics included making payments to physicians employed in state government, using questionable studies, and paying kickbacks to doctors who prescribed Risperdal.
Johnson & Johnson Pays $2.2 Billion in Risperdal Class Action Settlement
November 2013 — Johnson & Johnson (J&J) will pay $2.2 billion in a settlement to the U.S. Department of Justice (DOJ). Attorneys filed civil and criminal lawsuits after uncovering evidence that J&J illegally marketed Risperdal “off-label” in children, ignored FDA warnings and studies linking Risperdal to gynecomastia (male breast growth) in children, and paid kickbacks to doctors. Click here to read more.
Risperdal Lawsuit Settlements
Johnson & Johnson (J&J) has already settled several individual Risperdal lawsuits with young men who developed gynecomastia. The first settlement was given to a 21 year-old man who developed breasts after taking Risperdal when he was 9 years old. In October 2012, J&J agreed to four more settlements before trials could begin.
The Schmidt Firm, PLLC has been recognized as one of the nation’s leading plaintiffs' law firms and handles cases in all 50 states. We are very proud of our legal achievements, but equally self-respecting of our firm's reputation for providing personal attention to each and every client we represent.
